New Research Published in Nature Links Clinical Activity with HIF‐2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
AI Briefing
- • Arcus Biosciences announces new research in Nature on casdatifan's link to HIF-2a biology in advanced kidney cancer.
- • The ARC-20 study evaluated casdatifan as a monotherapy in patients with metastatic clear cell renal carcinoma.
- • The research aims to understand the clinical activity of casdatifan in treating advanced kidney cancer patients.
Source Summary
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a publication in Nature describing new research from the ARC-20 study. The publication evaluated casdatifan, an investigational, small-molecule HIF-2a inhibitor, as a monotherapy in patients with metastatic clear cell rena
Advertisement